1047 related articles for article (PubMed ID: 26584802)
1. How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?
Samuel AM; Rathi VK; Grauer JN; Ross JS
Clin Orthop Relat Res; 2016 Apr; 474(4):1053-68. PubMed ID: 26584802
[TBL] [Abstract][Full Text] [Related]
2. Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979-2015.
Gopal AD; Rathi VK; Teng CC; Del Priore L; Ross JS
Ophthalmology; 2017 Aug; 124(8):1237-1246. PubMed ID: 28501378
[TBL] [Abstract][Full Text] [Related]
3. Postmarket Modifications of High-Risk Therapeutic Devices in Otolaryngology Cleared by the US Food and Drug Administration.
Rathi VK; Ross JS; Samuel AM; Mehra S
Otolaryngol Head Neck Surg; 2015 Sep; 153(3):400-8. PubMed ID: 26044785
[TBL] [Abstract][Full Text] [Related]
4. Analysis of FDA-Approved Orthopaedic Devices and Their Recalls.
Day CS; Park DJ; Rozenshteyn FS; Owusu-Sarpong N; Gonzalez A
J Bone Joint Surg Am; 2016 Mar; 98(6):517-24. PubMed ID: 26984921
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011.
Rathi VK; Krumholz HM; Masoudi FA; Ross JS
JAMA; 2015 Aug; 314(6):604-12. PubMed ID: 26262798
[TBL] [Abstract][Full Text] [Related]
6. FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012.
Rome BN; Kramer DB; Kesselheim AS
JAMA; 2014 Jan 22-29; 311(4):385-91. PubMed ID: 24449317
[TBL] [Abstract][Full Text] [Related]
7. Recalls of Moderate- and High-Risk Otolaryngologic Devices Approved by the US Food and Drug Administration, 2003-2019.
Talati IA; Parsa KM; Gao WZ
Otolaryngol Head Neck Surg; 2022 Nov; 167(5):832-838. PubMed ID: 35290135
[TBL] [Abstract][Full Text] [Related]
8. Research: Evaluation of Orthopedic Hip Device Recalls by the FDA from 2007 to 2017.
Peters W; Pellerin C; Janney C
Biomed Instrum Technol; 2020 Nov; 54(6):418-426. PubMed ID: 33339030
[TBL] [Abstract][Full Text] [Related]
9. Medical device recalls and the FDA approval process.
Zuckerman DM; Brown P; Nissen SE
Arch Intern Med; 2011 Jun; 171(11):1006-11. PubMed ID: 21321283
[TBL] [Abstract][Full Text] [Related]
10. Risk of Recall Among Medical Devices Undergoing US Food and Drug Administration 510(k) Clearance and Premarket Approval, 2008-2017.
Dubin JR; Simon SD; Norrell K; Perera J; Gowen J; Cil A
JAMA Netw Open; 2021 May; 4(5):e217274. PubMed ID: 33956132
[TBL] [Abstract][Full Text] [Related]
11. Risk of Recall Associated With Modifications to High-risk Medical Devices Approved Through US Food and Drug Administration Supplements.
Dubin JR; Enriquez JR; Cheng AL; Campbell H; Cil A
JAMA Netw Open; 2023 Apr; 6(4):e237699. PubMed ID: 37043202
[TBL] [Abstract][Full Text] [Related]
12. Assessment of cardiovascular and noncardiovascular medical device recalls.
Somberg JC; McEwen P; Molnar J
Am J Cardiol; 2014 Jun; 113(11):1899-903. PubMed ID: 24837271
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Obstetric and Gynecologic Food and Drug Administration Device Approvals and Recalls.
Galhotra S; Maurice J
J Minim Invasive Gynecol; 2018; 25(7):1281-1288. PubMed ID: 29653261
[TBL] [Abstract][Full Text] [Related]
14. Orthopaedic Device Approval Through the Premarket Approval Process: A Financial Feasibility Analysis for a Single Center.
Yang BW; Iorio ML; Day CS
J Bone Joint Surg Am; 2017 Mar; 99(6):e26. PubMed ID: 28291189
[TBL] [Abstract][Full Text] [Related]
15. Postmarket Modifications of High-risk Plastic Surgery Devices.
Olaiya OR; Oyesile D; Stone N; Mbuagbaw L; McRae MH
Plast Reconstr Surg Glob Open; 2020 Feb; 8(2):e2621. PubMed ID: 32309074
[TBL] [Abstract][Full Text] [Related]
16. Software-Related Recalls of Health Information Technology and Other Medical Devices: Implications for FDA Regulation of Digital Health.
Ronquillo JG; Zuckerman DM
Milbank Q; 2017 Sep; 95(3):535-553. PubMed ID: 28895231
[TBL] [Abstract][Full Text] [Related]
17. Spinal devices in the United States-investigational device exemption trials and premarket approval of class III devices.
Golish SR; Reed ML
Spine J; 2017 Jan; 17(1):150-157. PubMed ID: 27737804
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of Clinical Studies Used for US Food and Drug Administration Approval of High-Risk Medical Device Supplements.
Zheng SY; Dhruva SS; Redberg RF
JAMA; 2017 Aug; 318(7):619-625. PubMed ID: 28810022
[TBL] [Abstract][Full Text] [Related]
19. Assessing the safety and effectiveness of devices after US Food and Drug Administration approval: FDA-mandated postapproval studies.
Reynolds IS; Rising JP; Coukell AJ; Paulson KH; Redberg RF
JAMA Intern Med; 2014 Nov; 174(11):1773-9. PubMed ID: 25265209
[TBL] [Abstract][Full Text] [Related]
20. Transparency and Dermatologic Device Approval by the US Food and Drug Administration.
Ezaldein HH; Scott JF; Yin ES; Ventura A; DeRuyter NP; Leffell DJ
JAMA Dermatol; 2018 Mar; 154(3):273-280. PubMed ID: 29365020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
